Inadvertent GLP-1 exposure around conception: counsel calmly, then stop the drug

Design

Systematic review and meta-analysis of cohort and observational studies

Population

22 studies, 49,395 pregnancies exposed around conception

Primary outcome

Malformations, pregnancy and delivery outcomes

Effect

No significant association for major malformations or preterm birth; renal malformations OR 1.23 (95% CI 1.09-1.39)

More women of reproductive age are taking GLP-1 receptor agonists, and some conceive while on them. This meta-analysis, published in April, pooled 22 studies covering 49,395 exposed pregnancies, with 10 cohort studies in the main analysis.

Exposure around conception was not associated with major or cardiac malformations, preterm birth, pregnancy loss, hypertensive disorders or caesarean delivery. A small association with renal malformations appeared (OR 1.23, 95% CI 1.09-1.39), but it came largely from one big cohort with marked baseline differences, and the authors judge it likely to reflect confounding by maternal diabetes and obesity.

This is observational evidence. It reassures after an unplanned exposure; it does not make these drugs suitable for use in pregnancy.

Ask about GLP-1 use at booking and at preconception visits, since it is often not volunteered. Where exposure has happened, explain that current evidence does not show a consistent harm, stop the drug, and plan glucose and growth care as for the underlying condition.

• Ask every woman at booking and preconception whether she uses a GLP-1 receptor agonist, including for weight loss.
• Pooled data did not link periconception exposure to major malformations, preterm birth or miscarriage.
• A small renal malformation signal likely reflects maternal disease rather than the drug.
• Stop the drug once pregnancy is confirmed and manage the underlying diabetes or obesity.
• Discuss contraception with women starting these drugs who do not plan pregnancy.

Why it matters

Exposed pregnancies are rising, and fear of harm can drive requests to end a wanted pregnancy that the evidence does not support.

Don't overread it

These are observational data — they reassure after exposure but do not make GLP-1 drugs safe to use in pregnancy.

The statistics, in plain English

An odds ratio of 1.23 for renal malformations is a small relative increase. Because it rests mostly on one cohort with baseline imbalances, it is weak evidence of a drug effect. No association for other outcomes means no consistent signal, not proof of zero risk.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.